Pharmagreen Biotech Inc. (PHBI)
| Previous Close | 0.0019 |
| Open | 0.0018 |
| Bid | 0.0022 x 0 |
| Ask | 0.0025 x 0 |
| Day's Range | 0.0018 - 0.0025 |
| 52 Week Range | 0.0003 - 0.0047 |
| Volume | |
| Avg. Volume | 6,669,614 |
| Market Cap | 1.46M |
| Beta (5Y Monthly) | 1.98 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0000 |
| Earnings Date | Sep 05, 2024 - Sep 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswirePharmagreen Biotech Inc. (PHBI) Announces Exciting Revenue Potential for Its Project
CARSON CITY, Nev., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Pharmagreen Biotech, Inc. (OTC PINKS: PHBI) ("Pharmagreen" or the "Company") is thrilled to highlight the significant revenue potential from its latest project under development. During a special session on Creative Spaces, hosted on X on Monday, October 7, 2024, CEO Peter Wojcik shared exciting insights into the company's business advancements and growth strategies. Pharmagreen is developing a specialized form of cannabis oil known as Live Ro
- GlobeNewswire
Pharmagreen Biotech, Inc. (PHBI) Reaffirms Commitment to Non-Toxic Financing Amid Ongoing Business Development Progress
CARSON CITY, NV, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Pharmagreen Biotech, Inc. (OTC PINKS: PHBI) ("Pharmagreen" or the "Company") is pleased to announce the continued advancement of its business development efforts on a significant project in collaboration with a foreign government. Considerable progress has been made, and the Company is optimistic about the wide-ranging benefits this initiative will bring to all involved parties. By incorporating Pharmagreen’s proprietary Standard Organic Non-Sp
